Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Basu, Bristi"'
Autor:
Balakrishnan, Anita, Barmpounakis, Petros, Demiris, Nikolaos, Jah, Asif, Spiers, Harry V M, Talukder, Shibojit, Martin, Jack L, Gibbs, Paul, Harper, Simon J F, Huguet, Emmanuel L, Kosmoliaptsis, Vasilis, Liau, Siong S, Praseedom, Raaj K, Basu, Bristi, de Aretxabala, Xavier, Lendoire, Javier, Maithel, Shishir, Branes, Alejandro, Andersson, Bodil, Serrablo, Alejandro, Adsay, Volkan
BackgroundGallbladder cancer (GBC) is rare but aggressive. The extent of surgical intervention for different GBC stages is non-uniform, ranging from cholecystectomy alone to extended resections including major hepatectomy, resection of adjacent organ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______109::a05489d4c92c5363ba18e0e668b0cd28
https://www.repository.cam.ac.uk/handle/1810/349630
https://www.repository.cam.ac.uk/handle/1810/349630
Autor:
Balakrishnan, Anita, Barmpounakis, Petros, Demiris, Nikolaos, Jah, Asif, Spiers, Harry VM, Talukder, Shibojit, Martin, Jack L, Gibbs, Paul, Harper, Simon JF, Huguet, Emmanuel L, Kosmoliaptsis, Vasilis, Liau, Siong S, Praseedom, Raaj K, Basu, Bristi, de Aretxabala, Xavier, Lendoire, Javier, Maithel, Shishir, Branes, Alejandro, Andersson, Bodil, Serrablo, Alejandro, Adsay, Volkan, OMEGA Study Investigators
BACKGROUND: Gallbladder cancer (GBC) is rare but aggressive. The extent of surgical intervention for different GBC stages is non-uniform, ranging from cholecystectomy alone to extended resections including major hepatectomy, resection of adjacent org
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f77cda856488fdcd1f2ecceaed2dd161
Autor:
Leineweber, Can G., Rabehl, Miriam, Pietzner, Anne, Rohwer, Nadine, Rothe, Michael, Pech, Maciej, Sangro, Bruno, Sharma, Rohini, Verslype, Chris, Basu, Bristi, Sengel, Christian, Ricke, Jens, Schebb, Nils Helge, Weylandt, Karsten-H., Benckert, Julia
Peer reviewed: True
Acknowledgements: We thank the SORAMIC research group for providing the samples, recruiting patients, collecting patient information, and processing blood samples, and the patients for their participation. This research was s
Acknowledgements: We thank the SORAMIC research group for providing the samples, recruiting patients, collecting patient information, and processing blood samples, and the patients for their participation. This research was s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e5d02d4c65718d2ec248e3e77223b98
Autor:
Funingana, Ionut-Gabriel, Piyatissa, Pubudu, Reinius, Marika, McCague, Cathal, Basu, Bristi, Sala, Evis
Clinical trials for oncology drug development have long relied on surrogate outcome biomarkers that assess changes in tumor burden to accelerate drug registration (i.e., Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cbdfd1f0abd62434ca285e75b8a2fc1
https://www.repository.cam.ac.uk/handle/1810/342194
https://www.repository.cam.ac.uk/handle/1810/342194
Autor:
Martins, Filipe Correia, Couturier, Dominique-Laurent, De Santiago, Ines, Sauer, Carolin Margarethe, Vias, Maria, Angelova, Mihaela, Sanders, Deborah, Piskorz, Anna, Hall, James, Hosking, Karen, Amirthanayagam, Anumithra, Cosulich, Sabina, Carnevalli, Larissa, Davies, Barry, Watkins, Thomas BK, Funingana, Ionut G, Bolton, Helen, Haldar, Krishnayan, Latimer, John, Baldwin, Peter, Crawford, Robin, Eldridge, Matthew, Basu, Bristi, Jimenez-Linan, Mercedes, Mcpherson, Andrew W, McGranahan, Nicholas, Litchfield, Kevin, Shah, Sohrab P, McNeish, Iain, Caldas, Carlos, Evan, Gerard, Swanton, Charles, Brenton, James D
Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma (HGSOC). Here we show that somatic copy number alterations (SCNAs) in frequently amplified HGSOC cancer genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d69ddda80d7c7a21c086c886d93bc14
Autor:
Dayimu, Alimu, Di Lisio, Lorena, Anand, Shubha, Roca-Carreras, Isart, Qian, Wendi, Al-Mohammad, Abdulrahman, Basu, Bristi, Valle, Juan W, Jodrell, Duncan, Demiris, Nikos, Corrie, Pippa
Publikováno v:
Dayimu, A, Di lisio, L, Anand, S, Roca-Carreras, I, Qian, W, Al-Mohammad, A, Basu, B, Valle, J W, Jodrell, D, Demiris, N & Corrie, P 2023, ' Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma ', British Journal of Cancer . https://doi.org/10.1038/s41416-023-02170-9
Background Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking. Methods Patient performance status, tumour b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f6f961281057ebf434789cada47c0a
https://research.manchester.ac.uk/en/publications/93e40767-1516-4b99-9a15-0cc232350fe3
https://research.manchester.ac.uk/en/publications/93e40767-1516-4b99-9a15-0cc232350fe3
Autor:
Schütte, Kerstin, Kupčinskas, Juozas, Morkunas, Egidijus, Öcal, Osman, Schinner, Regina, Seidensticker, Max, De Toni, Enrico N, Ben Khaled, Najib, Pech, Maciej, Palmer, Daniel, Berg, Thomas, Sengel, Christian, Basu, Bristi, Valle, Juan W, Benckert, Julia, Gasbarrini, Antonio, Sangro, Bruno, Malfertheiner, Peter, Ricke, Jens
IntroductionPrediction of response to treatment in patients with advanced hepatocellular carcinoma (HCC) may assist in the selection of personalized management.ObjectiveThis exploratory analysis of the palliative arm of the SORAMIC trial (ClinicalTri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa986510245dd1d018eb8921d4bf3518
Autor:
Schütte, Kerstin, Kupčinskas, Juozas, Morkunas, Egidijus, Öcal, Osman, Schinner, Regina, Seidensticker, Max, De Toni, Enrico N., Ben Khaled, Najib, Pech, Maciej, Palmer, Daniel, Berg, Thomas, Sengel, Christian, Basu, Bristi, Valle, Juan W., Benckert, Julia, Gasbarrini, Antonio, Sangro, Bruno, Malfertheiner, Peter, Ricke, Jens
Publikováno v:
Frontiers in Gastroenterology. 1
IntroductionPrediction of response to treatment in patients with advanced hepatocellular carcinoma (HCC) may assist in the selection of personalized management.ObjectiveThis exploratory analysis of the palliative arm of the SORAMIC trial (ClinicalTri
Autor:
Zaccagna, Fulvio, McLean, Mary A, Grist, James T, Kaggie, Joshua, Mair, Richard, Riemer, Frank, Woitek, Ramona, Gill, Andrew B, Deen, Surrin, Daniels, Charlie J, Ursprung, Stephan, Schulte, Rolf F, Allinson, Kieren, Chhabra, Anita, Laurent, Marie-Christine, Locke, Matthew, Frary, Amy, Hilborne, Sarah, Patterson, Ilse, Carmo, Bruno D, Slough, Rhys, Wilkinson, Ian, Basu, Bristi, Wason, James, Gillard, Jonathan H, Matys, Tomasz, Watts, Colin, Price, Stephen J, Santarius, Thomas, Graves, Martin J, Jefferies, Sarah, Brindle, Kevin M, Gallagher, Ferdia A
Purpose To evaluate glioblastoma (GBM) metabolism by using hyperpolarized carbon 13 (13C) MRI to monitor the exchange of the hyperpolarized 13C label between injected [1-13C]pyruvate and tumor lactate and bicarbonate. Materials and Methods In this pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d3890c3d5c78bee5e50a35fea2ab480
https://www.repository.cam.ac.uk/handle/1810/337518
https://www.repository.cam.ac.uk/handle/1810/337518
Autor:
Yap, Timothy A, Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J, Lim, Joline SJ, Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C, Ruddle, Ruth, Raynaud, Florence I, Decordova, Shaun, Swales, Karen E, Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin PO, Foxley, Andrew, Lord, Christopher J, Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S, Drew, Yvette, De Bono, Johann S
Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d965350921fdb45cf7f96f6c6697826
https://www.repository.cam.ac.uk/handle/1810/306749
https://www.repository.cam.ac.uk/handle/1810/306749